At a glance
Genomic tumor profiling is a laboratory test that reads the DNA of a patient's cancer cells to identify the specific gene changes driving that particular tumor.
Cancer grows when genes inside a cell become damaged or altered. Not every tumor has the same alterations, even when two patients have the same cancer type. Genomic profiling maps out those unique changes, giving oncologists (cancer specialists) a molecular fingerprint of the tumor. That fingerprint is then used to match the patient to targeted therapies, immunotherapy drugs, or clinical trials that are designed to act on exactly those alterations, rather than relying on a one-size-fits-all treatment plan.
Medical Condition
Genomic tumor profiling is used when oncologists need a deeper understanding of a cancer's biology to guide treatment decisions, especially when standard therapies have stopped working or a rare tumor is involved.
- Solid tumors such as lung, breast, colorectal, and ovarian cancer, particularly at an advanced or metastatic (spread to other organs) stage.
- Cancers that have not responded to first-line chemotherapy and where targeted therapy options are being explored.
- Rare or difficult-to-classify tumors where the tissue origin is uncertain.
- Blood cancers such as leukemia (cancer of the blood) or lymphoma (cancer of the lymphatic system) when genetic subtype affects treatment choice.
- Patients being considered for clinical trials that require a specific genetic mutation (gene change) as an entry criterion.
- Hereditary cancer syndromes, to identify whether a mutation that may affect family members is present in the tumor.
Profiling is not always the right first step. Oncologists generally do not request it when a standard, well-proven treatment is available and the genetic result would not change the plan. It is also less useful when the tumor sample is too small or degraded to yield reliable results, or when the patient's overall health would not allow any additional treatment regardless of what the test finds.
- Tumors where a single, already-known mutation test is sufficient and cheaper.
- Early-stage cancers with a clear and effective standard treatment protocol.
- Cases where the tissue biopsy sample is inadequate for sequencing.
- Situations where results would not affect the treatment plan in any meaningful way.
Risks & Complications
Genomic tumor profiling is a laboratory analysis of tissue or blood, so the test itself carries no direct physical risk to the patient once the sample has been collected.
- The main risk lies in how the tumor sample was obtained. If a new biopsy (tissue sample) was taken specifically for this test, that biopsy carries its own procedural risks, such as bleeding, infection, or discomfort at the biopsy site, depending on which organ was sampled.
- A liquid biopsy (a blood draw used to capture tumor DNA circulating in the bloodstream) carries only the minor risks of any routine blood draw, such as brief pain or a small bruise at the needle site.
- The test may return an inconclusive or uninterpretable result if the sample quality was poor, which could require a repeat biopsy.
- The test may identify a genetic variant of uncertain significance, meaning a gene change whose clinical impact is not yet understood. This can cause anxiety without providing clear direction.
- Incidental findings relating to inherited cancer risk may be discovered and may have emotional or family implications that require genetic counselling.
Preparation & Procedure
For the genomic profiling test itself, there is usually no fasting, no medication pause, and no special diet required. The preparation the patient experiences depends almost entirely on how the tumor sample will be collected.
If the profiling laboratory will use a tissue block that was already taken during a previous biopsy or surgery, no new procedure is needed. The oncology team retrieves the stored block and sends it to the genomics laboratory. If a fresh biopsy is required, preparation follows the rules for that specific biopsy type, which may include fasting, pausing blood thinners, or arranging local or general anaesthesia (medication that prevents pain).
If a liquid biopsy (blood-based test) is planned, preparation is minimal: usually just a routine blood draw with no fasting beforehand unless the treating team requests it.
Before any new sample is taken, the clinical team typically runs a set of baseline checks. These may include:
- A review of previous pathology (tissue analysis) reports and imaging scans to confirm tumour location and confirm enough material exists.
- Blood tests to check clotting function, especially if an invasive biopsy is planned.
- A discussion with the patient about what the test can and cannot reveal, including the possibility of uncertain results, usually handled by a genetic counsellor or oncologist.
When a fresh tissue biopsy is needed, the steps on the day usually follow this order:
- 1. The patient arrives and identity and consent forms are confirmed.
- 2. The biopsy site is located using imaging guidance such as CT or ultrasound.
- 3. The skin is cleaned and local anaesthetic (numbing medication) is given.
- 4. A needle or small cutting instrument is passed to the target tissue and a sample is removed.
- 5. Pressure or a small dressing is applied to the site.
- 6. The sample is labelled and sent to the genomics laboratory.
- 7. The patient is observed briefly to confirm there are no immediate complications before being discharged or returned to the ward.
Laboratory processing, sequencing, and report generation typically take from a few days to several weeks, depending on the depth of the analysis and the laboratory's workload.
Aftercare
Recovery from the profiling test itself is determined by whatever procedure was used to collect the sample, not by the laboratory work that follows.
- If a stored tissue block was used, no physical recovery is needed and the patient continues their usual activities immediately.
- After a liquid biopsy (blood draw), most patients resume normal activity within minutes. The puncture site should be kept clean and dry for a short period.
- After an image-guided tissue biopsy, the patient is usually observed for a brief period at the clinic or hospital and then discharged the same day in most cases. Strenuous activity is often restricted for a day or two.
- The biopsy site should be monitored for signs of bleeding, swelling, or infection, and the care team should be contacted if these appear.
- Pain at the biopsy site, if any, is typically mild and managed with over-the-counter pain relief as directed by the clinical team.
- A results discussion appointment should be scheduled in advance, as the reporting timeline varies. Results are usually reviewed in a multidisciplinary tumour board (a meeting of specialists from different fields) before being communicated to the patient.
- Patients who receive results indicating an inherited mutation are typically referred for genetic counselling and may be advised to inform close family members.
- Once results are available, follow-up care focuses on the treatment plan that the findings support, which may include targeted therapy, immunotherapy, enrolment in a clinical trial, or a continued standard treatment approach.
Cost & What Determines It
Genomic tumor profiling spans a wide price range because the depth of the analysis, the technology platform used, and the setting where the test is performed all vary considerably from one patient to the next.
- Scope of the panel: a small panel that checks a handful of known cancer genes costs far less than a whole-exome or whole-genome sequencing analysis that reads thousands of genes simultaneously.
- Type of sample: liquid biopsy (blood-based) panels and tissue-based panels have different laboratory costs, and a new biopsy procedure adds its own charge on top of the sequencing fee.
- Hospital or laboratory class: an academic cancer centre with an in-house sequencing facility charges differently from a community hospital that outsources samples to a reference laboratory in another country.
- Country where the test is performed: laboratory costs, regulatory requirements, and technology access differ markedly between countries, which is often the main reason patients consider travelling for this test.
- Turnaround time: some laboratories offer expedited reporting for an additional charge when treatment decisions are urgent.
- Pathology review: an expert pathologist (tissue analysis specialist) may review the sample before or after sequencing, adding a professional fee.
- Genetic counselling: a pre- or post-test session with a genetic counsellor is often billed separately.
- Repeat testing: if the sample quality is insufficient and a new biopsy is needed, the sequencing cost is incurred again.
A hospital package for genomic profiling often includes the sequencing run, the bioinformatics (computer analysis of gene data) interpretation, and a written clinical report. The cost of obtaining a new biopsy, anaesthesia, imaging guidance, pathology review, genetic counselling, and any follow-up consultation to discuss results is usually itemised and billed separately.
Indonesian patients travelling abroad for genomic tumor profiling should be aware that BPJS Kesehatan does not cover medical treatment received outside Indonesia, and most Indonesian private health insurance policies also exclude overseas care. Treatment costs are therefore typically paid out of pocket or through an international private medical insurance policy that explicitly covers treatment abroad. Requesting a detailed written cost estimate from the treating hospital before travelling is the most reliable way to understand the full expected expenditure and avoid unexpected charges on arrival.
Frequently Asked Questions
Does genomic tumor profiling hurt?
The test itself is not painful. It is done on a tissue sample that was already removed during a previous biopsy or surgery, so no new needle or cut is needed in most cases. If a fresh sample is required, a small biopsy is performed, and your doctor will use local anaesthetic to numb the area first.
How long does genomic tumor profiling take to get results?
Results usually take two to four weeks from the time the laboratory receives your sample. The lab reads the genetic code of the tumor cells, which is a detailed process that cannot be rushed without affecting accuracy. Your oncologist will schedule a follow-up appointment to walk through the findings with you.
How do I prepare for genomic tumor profiling?
In most cases, no special preparation is needed from you because the test is performed on tissue that has already been collected. If a new biopsy is needed to get a fresh sample, your doctor will give you specific instructions beforehand, such as whether to avoid blood-thinning medicines for a few days. There are no fasting requirements for the test itself.
How much does genomic tumor profiling cost?
The cost depends on which panel is ordered, meaning how many genes the laboratory analyses at once, as well as whether a new biopsy is needed to collect fresh tissue. Some panels examine a handful of genes while others scan hundreds, and that range in scope drives a large difference in price. Requesting a written estimate from your chosen hospital is the most reliable way to get a real number for your situation.
This page is general information, not a substitute for medical advice. Every case is different. Your doctor decides what is right for you.
